72 results
Page 3 of 4
8-K
EX-99.1
r74isrb
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-99.1
jhydp4ra54l97ax 0hdw
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-99.2
hfnhckgrcvn7gogt46
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
71b46ys6mayvueewfe
5 Oct 20
Prospectus supplement with pricing info
4:16pm
8-K
EX-99.1
kn3kxe3 ltqih
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
c36dq58x5z4nqage lu
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.2
jo1p3b
1 Jun 20
Entry into a Material Definitive Agreement
7:01am
8-K
EX-99.1
haz63
30 Mar 20
Processa Pharmaceuticals to Move Forward with a PCS499 Phase 3 Trial after a Successful Fda Meeting
4:00pm
8-K
EX-99.1
scuoz k73
17 Mar 20
Processa Pharmaceuticals Announces Results from the Phase 2 Study In Necrobiosis Lipoidica
9:30am
8-K
EX-99.1
qv4mr0ce f2vry9pnq0
5 Mar 20
Processa Pharmaceuticals Announces Formation of Its Medical and Scientific Advisory Board
9:30am
8-K
EX-99.1
v91n3ao0qt73r6dwq
25 Feb 20
Processa Pharmaceuticals Provides Shareholder Update
9:30am
8-K
EX-99.1
794 x6jh3g
13 Feb 20
Processa Pharmaceuticals Appoints
9:30am
8-K
EX-99.1
y1zv1pcchu3ymxg89 pl
20 Dec 19
Processa Pharmaceuticals Announces 1 for 7 Reverse Stock Split of Its Common Stock
4:20pm
8-K
EX-99.2
fc0s3x
4 Sep 19
Entry into a Material Definitive Agreement
5:19pm